Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827367 | 0.88 | TK1 (0.44) | ALDH1A1POLBTK1 | |
| SCHEMBL6258952 | 0.87 | TK1 (0.43) | KMT2ATK1PYGMP2RY6 | |
| SCHEMBL9744721 | 0.87 | LMNA (0.43) | SMN1; SMN2TK1P2RY6 | |
| SCHEMBL8167928 | 0.87 | TK2 (0.37) | TK1 | |
| SCHEMBL8176114 | 0.86 | TK1 (0.33) | TK1 | |
| SCHEMBL9803727 | 0.83 | TK1 (0.36) | TK1 | |
| SCHEMBL4366634 | 0.81 | SLC28A1 (0.36) | P2RY6 | |
| SCHEMBL9745084 | 0.79 | SQOR (0.44) | ALDH1A1POLBKMT2ASMN1; SMN2TK1 | |
| SCHEMBL7024107 | 0.79 | HTT (0.38) | ALDH1A1KMT2ATK1 | |
| SCHEMBL766611 | 0.76 | PYGM (0.41) | ALDH1A1POLBKMT2ASMN1; SMN2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | disclosed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6951931-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5434257-A | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages | GILEAD SCIENCES, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995011911-A1 | BINDING COMPETENT OLIGOMERS CONTAINING UNSATURATED 3',5' AND 2',5' LINKAGES | GLAXO WELLCOME INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5175273-A | Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings | GENENTECH, INC. (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | ALDH1A1 2172/4885POLB 174/4885KMT2A 2645/4885 |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | ALDH1A1 2764/4885POLB 80/4885KMT2A 2573/4885 |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | RBBP4, DDB1, DPYD | ALDH1A1 2414/4885POLB 233/4885KMT2A 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.